Galpharm's non-prescription generic migraine tablet gets second knockback
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's scientific committee, the CHMP, has again issued a negative opinion for Galpharm Healthcare's Sumatriptan Galpharm 50mg, a non-prescription migraine treatment.